Scientific jobs

Scientific jobs

As a scientific officer at EMA, you will typically be responsible for activities related to human or veterinary medicines in areas such as procedure and scientific management, scientific committee support, pharmacovigilance, and inspections and quality.

You will have obtained a degree in a science field and have proven work experience in the field of medicines regulation from the pharmaceutical industry, a national competent authority or academia. You will have knowledge and understanding of scientific aspects of medicines development, clinical trials methodology, signal detection and pharmacoepidemiology. You will be a curious, solution-driven team player who can communicate verbally and in writing with various audiences.

Title Deadline for application Type of position
Trainee (Refining regulatory intelligence on not-for-profit medicine developments) 30 September 2026 23:59 CEST Trainee
Head of Department: Veterinary Evaluation and Innovation Department (V-EI) 13 September 2026 at 23.59 CET Temporary agent
SNE/Scientific Specialist (Veterinary Biologicals and Emerging Therapies)
SNE/Scientific Specialist (Veterinary Biologicals and Emerging Therapies) 21 September 2026 at 23.59 CET Seconded National Expert
21 September 2026 at 23.59 CET Seconded National Expert
Trainee(Exploring development of a mobile app to make veterinary e-leaflets available to the public) 30 September 2026 23:59 CEST Trainee
Trainee (Analysis of EU Strategic and legal provisions promoting Innovation in Pharma) 30 September 2026 23:59 CEST Trainee
Trainee (Development of medicines for children and paediatric pharmacovigilance) 30 September 2026 23:59 CEST Trainee

What is it like to work in the Human Medicines Division?

Regulatory Science to 2025 - Shaping the future

 

As science and technology advance and bring potential new treatments and diagnostic tools, regulatory science must advance in tandem so that these can be correctly, rigorously and efficiently assessed. Examples of the transformational research that is having a significant impact on the regulatory science agenda include cell-based therapies, genomics-based diagnostics, drug-device combinations, novel clinical trial design, predictive toxicology, real-world evidence, and ‘big data’ and artificial intelligence.